Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2014 Oct 28:5:5068.
doi: 10.1038/ncomms6068.

Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins

Iris Postmus  1 Stella Trompet  2 Harshal A Deshmukh  3 Michael R Barnes  4 Xiaohui Li  5 Helen R Warren  6 Daniel I Chasman  7 Kaixin Zhou  3 Benoit J Arsenault  8 Louise A Donnelly  3 Kerri L Wiggins  9 Christy L Avery  10 Paula Griffin  11 QiPing Feng  12 Kent D Taylor  5 Guo Li  9 Daniel S Evans  13 Albert V Smith  14 Catherine E de Keyser  15 Andrew D Johnson  16 Anton J M de Craen  1 David J Stott  17 Brendan M Buckley  18 Ian Ford  19 Rudi G J Westendorp  20 P Eline Slagboom  21 Naveed Sattar  22 Patricia B Munroe  6 Peter Sever  23 Neil Poulter  23 Alice Stanton  24 Denis C Shields  25 Eoin O'Brien  26 Sue Shaw-Hawkins  4 Y-D Ida Chen  5 Deborah A Nickerson  27 Joshua D Smith  27 Marie Pierre Dubé  8 S Matthijs Boekholdt  28 G Kees Hovingh  29 John J P Kastelein  29 Paul M McKeigue  30 John BetteridgeAndrew Neil  31 Paul N Durrington  32 Alex Doney  3 Fiona Carr  3 Andrew Morris  3 Mark I McCarthy  33 Leif Groop  34 Emma Ahlqvist  34 Welcome Trust Case Control ConsortiumJoshua C Bis  9 Kenneth Rice  35 Nicholas L Smith  36 Thomas Lumley  37 Eric A Whitsel  38 Til Stürmer  10 Eric Boerwinkle  39 Julius S Ngwa  11 Christopher J O'Donnell  40 Ramachandran S Vasan  41 Wei-Qi Wei  42 Russell A Wilke  43 Ching-Ti Liu  11 Fangui Sun  11 Xiuqing Guo  5 Susan R Heckbert  44 Wendy Post  45 Nona Sotoodehnia  46 Alice M Arnold  35 Jeanette M Stafford  47 Jingzhong Ding  48 David M Herrington  49 Stephen B Kritchevsky  50 Gudny Eiriksdottir  51 Leonore J Launer  52 Tamara B Harris  52 Audrey Y Chu  53 Franco Giulianini  53 Jean G MacFadyen  53 Bryan J Barratt  54 Fredrik Nyberg  55 Bruno H Stricker  56 André G Uitterlinden  57 Albert Hofman  58 Fernando Rivadeneira  59 Valur Emilsson  51 Oscar H Franco  60 Paul M Ridker  53 Vilmundur Gudnason  14 Yongmei Liu  48 Joshua C Denny  61 Christie M Ballantyne  62 Jerome I Rotter  5 L Adrienne Cupples  63 Bruce M Psaty  64 Colin N A Palmer  3 Jean-Claude Tardif  8 Helen M Colhoun  65 Graham Hitman  66 Ronald M Krauss  67 J Wouter Jukema  68 Mark J Caulfield  6
Collaborators, Affiliations
Meta-Analysis

Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins

Iris Postmus et al. Nat Commun. .

Abstract

Statins effectively lower LDL cholesterol levels in large studies and the observed interindividual response variability may be partially explained by genetic variation. Here we perform a pharmacogenetic meta-analysis of genome-wide association studies (GWAS) in studies addressing the LDL cholesterol response to statins, including up to 18,596 statin-treated subjects. We validate the most promising signals in a further 22,318 statin recipients and identify two loci, SORT1/CELSR2/PSRC1 and SLCO1B1, not previously identified in GWAS. Moreover, we confirm the previously described associations with APOE and LPA. Our findings advance the understanding of the pharmacogenetic architecture of statin response.

PubMed Disclaimer

Conflict of interest statement

B.M.P. serves on the Data and Safety Monitoring Board of a clinical trial funded by the device manufacturer (Zoll LifeCor). N.P. and A.S. received funding from Pfizer for the extended follow-up of the ASCOT UK participants. D.I.C. and P.M.R. received research support for independent genetic analysis in JUPITER from AstraZeneca. F.N. and B.J.B. have employment, stock and stock options in AstraZeneca, a for-profit company engaged in the discovery, development, manufacture and marketing of proprietary therapeutics such as rosuvastatin, but do not consider that this creates any conflict of interest with the subject-matter of this publication. R.M.K. serves on the Merck Global Atherosclerosis Advisory Board. The remaining authors declare no competing financial interests.

Figures

Figure 1
Figure 1. Results of the GWAS meta-analysis.
Manhattan plot presenting the −log10 P values from the combined meta-analysis (n=40,914) on LDL-C response after statin treatment. P values were generated using linear regression analysis.
Figure 2
Figure 2. Regional association plots of the genome-wide significant associations with LDL-C response after statin treatment.
The plots show the genome-wide significant associated loci in the combined meta-analysis (n=40,914), the APOE locus (a), the LPA locus (b), the SORT1/CELSR2/PSRC1 locus (c) and the SLCO1B1 locus (d) (generated using LocusZoom ( http://genome.sph.umich.edu/wiki/LocusZoom)). The colour of the SNPs is based on the LD with the lead SNP (shown in purple). The RefSeq genes in the region are shown in the lower panel. P values were generated using linear regression analysis.

References

    1. Davidson M. H. & Toth P. P. Comparative effects of lipid-lowering therapies. Prog. Cardiovasc. Dis. 47, 73–104 (2004). - PubMed
    1. Baigent C. et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376, 1670–1681 (2010). - PMC - PubMed
    1. Mangravite L. M., Thorn C. F. & Krauss R. M. Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J. 6, 360–374 (2006). - PubMed
    1. Postmus I. et al. Pharmacogenetics of statins: achievements, whole-genome analyses and future perspectives. Pharmacogenomics 13, 831–840 (2012). - PubMed
    1. Chasman D. I. et al. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291, 2821–2827 (2004). - PubMed

Publication types

MeSH terms

Substances

Grants and funding